Anti-c-erbB2-anti-CD3 bifunctional monoclonal antibodies

Drug Profile

Anti-c-erbB2-anti-CD3 bifunctional monoclonal antibodies

Alternative Names: Anti-c-erbB-2-anti-CD3-epsilon; Anti-CD3-anti-HER-2 monoclonal antibody; bifunctional antibody

Latest Information Update: 19 Dec 2006

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Otsuka Pharmaceutical
  • Class Antineoplastics; Monoclonal antibodies
  • Mechanism of Action CD3 antigen inhibitors; ERBB 2 receptor antagonists; T lymphocyte stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Discontinued Cancer

Most Recent Events

  • 10 Apr 1997 No-Development-Reported for Cancer in Japan (Parenteral)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top